5% Yielding Dividend Aristocrats You'll Want To Own In The Coming Bear Market

Apr. 05, 2022 2:20 PM ET, , , , , 60 Comments

Summary

  • The bond market is starting to signal that a recession and bear market could be coming in 2023 or 2024.
  • Market timing is NEVER the answer to avoiding bear markets and risks destroying 94% of your wealth over decades.
  • These 5% yielding, low-volatility Ultra SWAN quality aristocrats are 18% undervalued and expected to deliver 11.3% long-term returns, similar to the 12.6% returns they delivered over the last 25 years.
  • These aristocrats fell 4% less than a 60/40 retirement portfolio during the Great Recession, showcasing how quality, defensive blue-chips can help you sleep well at night in even the worst market conditions.
  • When combined with 3 low-cost ETFs these 5% yielding aristocrats create the ultimate Zen Ultra SWAN low volatility high-yield retirement portfolio, which fell just 9% in the pandemic crash, andjust17% during the Great Recession.
  • Looking for a portfolio of ideas like this one? Members of The Dividend Kings get exclusive access to our model portfolio. Learn More »
happy couple on the beach

anyaberkut/iStock via Getty Images

For now, the stock market is partying like the good times are back and will never end.

But we all know that at some point a recession is coming and with it a bear market.

Recession Watch

Bonds Yield

----------------------------------------------------------------------------------------

Dividend Kings helps you determine the best safe dividend stocks to buy via our Automated Investment Decision Tool, Research Terminal, correction planning tool, Company Screener, and Daily Blue-Chip Deal Videos.

Membership also includes

  • Access to our 10 model portfolios (each is beating the market in this correction)
  • my correction watchlist 
  • 50 exclusive articles per month
  • 50% discount to iREIT (our REIT focused sister service) 
  • real-time chatroom support
  • exclusive email updates to all my retirement portfolio trades 
  • numerous valuable investing tools 

Click here for a two-week free trial so we can help you achieve better long-term total returns and your financial dreams.

This article was written by

115.74K Followers

Dividend Sensei (Adam Galas) is an Army veteran and stock analyst with 20+ years of market experience.

He is a founding author of the investing group The Dividend Kings which focuses on helping investors safeguard and grow their money in all market conditions through the highest-quality dividend investments. Dividend Sensei and the team of analysts (Brad Thomas, Justin Law, Nicholas Ward, Chuck Carnevale, and Sebastian Wolf) help members invest more intelligently in dividend stocks. Features include: 13 model portfolios, buy ideas, company research reports, and a thriving chat community for readers looking to learn how to invest more intelligently in dividend stocks. Learn more.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of UGI, ENB, MO, MMM, NVS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Dividend Kings owns UGI, ENB, MO, MMM, and NVS in our portfolio.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ENB--
Enbridge Inc.
MMM--
3M Company
MO--
Altria Group, Inc.
NVS--
Novartis AG
UGI--
UGI Corporation

Related Analysis